The KCNA5 plasmid was from Dr Jie Zheng (University of California, Davis). The Cav-1 plasmid and siRNA plasmid specific for Cav-1 (target sequence Oligo 1, 5′-ACCTCATTAAGAGCTTCCTGATTGAGTCAAGAGCTCAATCAGGAAGCTCTTAATTT-3′, Oligo 2, 5′-CAAAAAATTAAGAGCTTCCTGATTGAGCTCTTGACTCAATCAGGAAGCTCTTAATG-3′) were obtained from the Cancer Center at Creighton University.
Anti-KCNA5 (rabbit polyclonal, 1:500; EMD Millipore, Billerica, MA, USA),
anti-Cav-1 (mouse monoclonal, 1:1,000, Santa cruz biotechnology),
anti-p-MAPK (mouse monoclonal, 1:1,000),
anti-MAPK (rabbit polyclonal, 1:1,000),
anti-p-AKT (rabbit monoclonal, 1:1,000) (all from Cell Signaling Technology, Danvers, MA, USA),
anti-AKT (goat polyclonal, 1:1,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), 1:500),
anti-PCNA (mouse monoclonal, 1:500) and
anti-β-actin (mouse monoclonal, 1:1,000) (all from Wuhan Boster Biological Technology, Ltd., Wuhan, China). HRP-conjugated goat anti-rabbit, anti-mouse or anti-goat specific secondary antibody (1:6,000; Zhongshan Golden Bridge Biotechnology, Beijing, China).
Qu C., Sun J., Liu Y., Wang X., Wang L., Han C., Chen Q., Guan T., Li H., Zhang Y., Wang Y., Liu J., Zou W, & Liu J. (2018). Caveolin-1 facilitated KCNA5 expression, promoting breast cancer viability. Oncology Letters, 16(4), 4829-4838.